35
Participants
Start Date
November 30, 2007
Primary Completion Date
February 18, 2008
Study Completion Date
February 18, 2008
PF-02545920
Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days
Placebo
Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
St. Anthony Hospital, Oklahoma City
IPS Research Company, Oklahoma City
California Clinical Trials Medical Group, Paramount
LaPaz Geropsychiatric Center, Paramount
California Clinical Trials Medical Group, Inc., Glendale
Glendale Adventist Medical Center, Glendale
Telecare-Cresta Loma, Lemon Grove
California Clinical Trials Medical Group, San Diego
Connecticut Mental Health Center-Yale University, Clinical Neuroscience Research Unit, New Haven
CRI Worldwide, LLC, Willingboro
Lead Sponsor
Pfizer
INDUSTRY